• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Varenicline therapy increases smoking cessation rates

byJohn PrendergassandPriyanka Vedak
February 18, 2015
in Chronic Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. When compared to placebo, varenicline use for 24 weeks significantly increased smoking cessation rates at 3 months and 1 year.

2. Although clinical guidelines suggest quitting abruptly, varenicline may be a treatment option for patients with whom this is not an option.

Evidence Rating Level: 1 (Excellent)

Study Rundown: According to the CDC, 42.1 million adults in the United States currently smoke cigarettes. This accounts for more than 480,000 deaths every year and more than 16 million living with a smoking-related disease in our country. A number of smoking aids are currently on the market, many of which are nicotine substitutes. Varenicline, also known by the brand name Chantix, is a partial agonist at nicotinic acetylcholine receptors. It has been shown to increase smoking abstinence rates among smokers seeking to quit abruptly, as well as reduce cigarette consumption among those not actively trying to stop.

This study determined that varenicline may also be a helpful option for smokers are making attempts to reduce the number of cigarettes smoked per day with the goal of quitting. Participants demonstrated increased rates of smoking cessation at 3 months and 1 year following a 24-week course of varenicline. Strengths of this study include its randomized design and large sample size. It is limited by the extensive use of counseling and support the participants received during the trial, options that may not be available to all patients in a real world clinical setting. Nevertheless, this study highlights yet another regimen that clinicians can offer their patients for smoking cessation.

Click to read the study, published today in JAMA

Relevant Reading: Efficacy of Varenicline to Prompt Quit Attempts in Smokers Not Currently Trying to Quit: A Randomized Placebo-Controlled Trial

RELATED REPORTS

Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

In-Depth [randomized controlled trial]: This study evaluated 1510 participants from 61 centers in 10 countries between July 2011-July 2013. Inclusion criteria included having smoked 10 cigarettes per day or greater, and being willing to quit smoking over the next 3 months but not within the month. Participants went through a 24-week treatment followed by 28-week follow-up. Treatment groups were varenicline (n=760) or placebo (n=750). The varenicline group had higher rates of abstinence during weeks 15-24 (32.1% for the varenicline group vs. 6.9% for the placebo group; RD 25.2%, 95%CI 21.4%-29.0%; RR 4.6, 95%CI 3.5-6.1). Further, between weeks 21-52 the varenicline group showed similarly higher rates of abstinence (27.0% for the varenicline group vs. 9.9% for the placebo group; RD 17.1%, 95%CI 13.3%-20.9%; RR 2.7, 95%CI 2.1-3.5). After 8 weeks, 26.3% of those in the varenicline group reduced smoking by 75% or abstained vs. 15.1% of those in the placebo group (RD 11.3%, 95%CI 7.2%- 15.3%; RR 1.8, 95%CI 1.4-2.2).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: smoking cessationvarenicline
Previous Post

Eliglustat decreases spleen size in Type I Gaucher disease [ENGAGE Trial]

Next Post

Fondaparinux effective as antithrombotic therapy in NSTEMI

RelatedReports

Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers

July 1, 2022
#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial
StudyGraphics

#VisualAbstract: Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

June 28, 2022
Strict tobacco licensing laws linked to reduced adolescent smoking initiation
Chronic Disease

Varenicline improves successful smoking cessation amongst African American daily smokers: KIS-IV Trial

June 15, 2022
Secondhand smoke exposure counseling may be insufficient amongst cardiology inpatients
Chronic Disease

Combination treatment with varenicline and nicotine patch improves smoking cessation outcomes for concurrent alcohol users

April 7, 2022
Next Post
β-blockers linked to improved survival in preserved ejection fraction heart failure

Fondaparinux effective as antithrombotic therapy in NSTEMI

Combined MRI and NIH stroke scores may predict stroke prognosis

Combined MRI and NIH stroke scores may predict stroke prognosis

Amyloid may cause distant cerebral hypometabolism in Alzheimer’s

Amyloid may cause distant cerebral hypometabolism in Alzheimer’s

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
  • Litifilimab associated with reduced disease severity in patients with cutaneous lupus erythematosus
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.